

HR 4087

Prescription Drug Labeling Promotion Act of 2012

Congress: 112 (2011–2013, Ended)

Chamber: House

Policy Area: Health

Introduced: Feb 24, 2012

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Feb 24, 2012)

Official Text: <https://www.congress.gov/bill/112th-congress/house-bill/4087>

Sponsor

Name: Rep. Markey, Edward J. [D-MA-7]

Party: Democratic • State: MA • Chamber: Senate

Cosponsors (10 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Moran, James P. [D-VA-8]	D · VA		Feb 29, 2012
Rep. Ros-Lehtinen, Ileana [R-FL-18]	R · FL		Feb 29, 2012
Rep. Bonamici, Suzanne [D-OR-1]	D · OR		Mar 28, 2012
Rep. Clay, Wm. Lacy [D-MO-1]	D · MO		Mar 28, 2012
Rep. Roe, David P. [R-TN-1]	R · TN		Mar 28, 2012
Rep. Smith, Adam [D-WA-9]	D · WA		Mar 28, 2012
Rep. Speier, Jackie [D-CA-12]	D · CA		Mar 28, 2012
Rep. McGovern, James P. [D-MA-3]	D · MA		May 8, 2012
Rep. Price, David E. [D-NC-4]	D · NC		May 8, 2012
Rep. Courtney, Joe [D-CT-2]	D · CT		Aug 2, 2012

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Feb 24, 2012

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
112 S 3187	Related bill	Jul 9, 2012: Became Public Law No: 112-144.
112 S 2516	Related bill	May 7, 2012: Placed on Senate Legislative Calendar under General Orders. Calendar No. 389.

Prescription Drug Labeling Promotion Act of 2012 - Directs the Secretary of Health and Human Services (HHS) to establish a working group to develop best practices on access to prescription drug labeling for the visually impaired.

Requires the working group to: (1) include equal representation of consumer and industry advocates; (2) promulgate guidance on best practices for pharmacies to ensure that blind and visually impaired individuals have safe, consistent, reliable, and independent access to the information in the labeling of prescription drugs; (3) consider the use of Braille, specified auditory means, and enhanced visual means to provide such access; and (4) consider whether there are technical, financial, manpower, or other factors that may fundamentally impact the ability of pharmacies with 20 or fewer retail locations to implement the best practices.

Directs the Commissioner of Food and Drugs (FDA) to conduct an informational and educational program to inform the public and pharmacists about such guidance and practices.

Directs the Comptroller General: (1) 18 months after such guidance and practices are published, to review pharmacy compliance and the extent to which access barriers continue; and (2) by September 30, 2016, to report on such review, including recommendations for reducing such barriers.

### **Actions Timeline**

---

- **Feb 24, 2012:** Introduced in House
- **Feb 24, 2012:** Referred to the House Committee on Energy and Commerce.